Efficacy of Mindfulness-Based Interventions on Anxiety and Sleep Quality in Patients with Breast Cancer: A Systematic Review and Meta-Analysis.

J Integr Complement MedJun 15, 2026 (epub)
Clinical ResearchOncology (Medical)

Yongmi Lee, Hyunju Kang, Myoungsuk Kim

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the impact of mindfulness-based interventions (MBIs) on anxiety and sleep quality in 3,212 breast cancer patients across 24 randomized controlled trials. The analysis found that MBIs significantly reduced anxiety compared to control groups (SMD: -0.47, 95% CI: -0.62 to -0.32), but did not significantly improve sleep quality.

Key findings

  • MBIs significantly reduced anxiety in breast cancer patients (SMD: -0.47, 95% CI: -0.62 to -0.32).
  • No significant effect of MBIs on sleep quality was observed.
  • Intervention duration accounted for 55.5% of the heterogeneity in anxiety outcomes.
  • All studies had some concerns regarding risk of bias.

Why it matters

Anxiety is a common and distressing symptom in breast cancer patients, and effective nonpharmacological interventions like MBIs may enhance patient quality of life. Understanding their efficacy can guide supportive care strategies.

What to keep in mind

All studies had concerns regarding risk of bias, primarily due to self-reported outcomes and lack of blinding.

Source

PubMed · PMID 42298832

Published in J Integr Complement Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.